FDA Panel Backs New Alzheimer’s Drug
The FDA advisory panel has recommended the approval of donanemab, a new Alzheimer’s drug by Eli Lilly, after voting unanimously that it effectively slows early-stage Alzheimer’s disease and that its benefits outweigh the risks.